There is substantial doubt about the company’s ability to persist as a going concern, as it needs financing to advance the ...

EO-3021 is a Claudin 18.2 antibody-drug conjugate ... Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and ...

Elevation Oncology (ELEV) announced that it has elected to discontinue development of EO-3021. EO-3021 is a Claudin 18.2 antibody-drug ...

EO-3021 is a Claudin 18.2 antibody-drug conjugate (ADC), which Elevation Oncology was developing for the treatment of advanced, unresectable or metastatic gastric and gastroesophageal junction ...